As the volume of treatment for patients with heart failure increases due to the aging population, the competition is accelerating in the market for the treatment.

This is because there are more treatment options in clinical practices and higher chances of generics entry into the market.

According to the medical and pharmaceutical industry on August 13th, the medicine market saw significant growth following major academic associations' revision to the guidelines for treating heart failure and the release of major new drugs.

In the current clinical practices, there are '4 pillars' strategy of standard therapy for treating heart failure consisting of 'ARNI/Angiotensin-Conver